Multivariate analyses verified that EGFR molecular subtypes, treatment patterns and ECOG PS were independent predictors of PFS for advanced NSCLC patients with EGFR uncommon alterations (p < 0.05, Table 4). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.